Concise Biothiol-Activatable HPQ-NBD Conjugate as a Targeted Theranostic Probe for Tumor Cells

Area of Science:

• Biomedical Engineering
• Chemical Biology
• Oncology

Background:

• Cancer poses a significant threat to human health, necessitating advancements in diagnosis and therapy.
• Current theranostic agents often suffer from complex structures and challenging synthesis, highlighting the need for simpler alternatives.
• Developing novel, efficient theranostic agents is crucial for improving cancer treatment outcomes.

Purpose of the Study:

• To design and synthesize a simple and efficient theranostic probe for cancer diagnosis and therapy.
• To investigate the probe's ability to differentiate between tumor and normal cells.
• To evaluate the probe's efficacy in selectively killing cancer cells.

Main Methods:

• A novel theranostic probe, HAPQ-NBD, was synthesized by combining the precipitated fluorophore HAPQ with NBD-Cl.
• The probe's mechanism relies on the differential levels of biothiol in tumor cells compared to normal cells.
• The probe's ability to release the fluorophore HAPQ in response to biothiol was utilized for targeted drug delivery.

Main Results:

• The HAPQ-NBD probe successfully distinguished between tumor and normal cells based on biothiol concentration.
• Biothiol acted as a switch to release the fluorophore HAPQ specifically within tumor cells.
• The released HAPQ demonstrated selective high toxicity towards tumor cells, leading to targeted cancer cell death.

Conclusions:

• The HAPQ-NBD probe represents a practical tool for simultaneous cancer diagnosis and therapy.
• The use of precipitated fluorophores offers a novel strategy for developing advanced cancer theranostics.
• This research provides a new method for selective cancer cell killing, advancing the field of oncology.